Takeda’s Elritercept Study Signals Long-Term Bet on MDS Anemia Innovation
at www.tipranks.com (Fri, 6-Feb 11:32 AM)
Takeda’s Fazirsiran Phase 3 Liver Study Progresses, Strengthening Its Rare-Disease Pipeline Story
at www.tipranks.com (Fri, 6-Feb 11:32 AM)
Takeda’s TAK-188 Trial: Early Immunotherapy Bet in Advanced Solid Tumors
at www.tipranks.com (Fri, 6-Feb 11:32 AM)
Takeda Advances TAK-360 Sleep Disorder Trial, Signaling Growing Ambition in Orexin-Based Therapies
at www.tipranks.com (Fri, 6-Feb 11:31 AM)
Takeda Advances Orexin-Mimicking Narcolepsy Drug TAK-360 Into Active Mid-Stage Testing
at www.tipranks.com (Fri, 6-Feb 11:31 AM)
Takeda Advances Elritercept Study in Myelofibrosis, Keeping Anemia-Focused Pipeline in the Spotlight
at www.tipranks.com (Thu, 5-Feb 11:32 AM)
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio
at seekingalpha.com (Thu, 5-Feb 8:15 AM)
Takeda’s Mezagitamab ITP Extension Study: Long-Term Data That Matters for Investors
at www.tipranks.com (Wed, 4-Feb 11:32 AM)
Takeda Advances Zasocitinib Trial in Vitiligo, Signaling Quiet but Important Pipeline Momentum
at www.tipranks.com (Wed, 4-Feb 11:32 AM)
Takeda Advances Zasocitinib Trial in Painful Skin Disease, Sharpening Its Immunology Pipeline
at www.tipranks.com (Wed, 4-Feb 11:31 AM)
Takeda Earnings Call: R&D Wins Amid Revenue Pressure
at www.tipranks.com (Mon, 2-Feb 7:02 PM)
Market Chameleon (Thu, 18-Dec 9:41 AM)
